Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years — United States, July 2022
Evelyn Twentyman(Synaptic Research (United States)), Sara E. Oliver(Centers for Disease Control and Prevention), Oliver Brooks, Hannah G. Rosenblum(National Center for Immunization and Respiratory Diseases), Katherine E. Fleming-Dutra(Centers for Disease Control and Prevention), Laura L. Daniel(American Academy of Family Physicians), Monica Godfrey, Grace M. Lee, Lauren E. Roper(National Center for Immunization and Respiratory Diseases), W. Roodly Archer(Center for Global Health), H. Keipp Talbot(Marshfield Clinic), Tara C. Anderson(National Center for Immunization and Respiratory Diseases), Megan J. Wallace(Hudson Institute), Beth P. Bell(Centers for Disease Control and Prevention), Amy B. Rubis(National Center for Immunization and Respiratory Diseases), Elisha Hall, Joy Hsu(National Center for Environmental Health), Matthew F. Daley(Kaiser Permanente), Sarah Meyer, Danielle Moulia(Centers for Disease Control and Prevention)
Cited by 31
Related Papers
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602
Potential Indirect Effects of the COVID-19 Pandemic on Use of Emergency Departments for Acute Life-Threatening Conditions — United States, January–May 2020
|MMWR Morbidity and Mortality Weekly Report|2020|378
Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021
|Preventing Chronic Disease|2021|370
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
|MMWR Morbidity and Mortality Weekly Report|2021|215